B. Riley Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

B. Riley Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$227	Buy	384 +62	+19%	+$40.3K	﹤0.01%	623
2022 Q1	$225K	Buy	+322	New	+$204K	0.02%	528
2020 Q3	–	Sell	-1,075	Closed	-$670K	–	506
2020 Q2	$670K	Buy	+1,075	New	+$610K	0.07%	198
2015 Q3	–	Sell	-200	Closed	-$102K	–	615
2015 Q2	$102K	Buy	+200	New	+$97.6K	0.08%	275

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

B. Riley Wealth Management's REGN Position: Q2 2022 in Review

B. Riley Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2022, buying an estimated $40.3K and bringing the position to 384 shares worth $227. The position accounts for ﹤0.01% of the portfolio, ranked #623.

B. Riley Wealth Management first reported a position in REGN in Q2 2015 and has held it in 4 quarters since. The position peaked at $670K in Q2 2020. 1,063 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

B. Riley Wealth Management held 384 shares of Regeneron Pharmaceuticals worth $227 as of Q2 2022.
B. Riley Wealth Management bought 62 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $40.3K.
Regeneron Pharmaceuticals made up ﹤0.01% of B. Riley Wealth Management's portfolio in Q2 2022, its #623 holding.
B. Riley Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 4 quarters since.
B. Riley Wealth Management's Regeneron Pharmaceuticals position peaked at $670K in Q2 2020.
1,063 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on B. Riley Wealth Management's 13F filing for Q2 2022, filed 9 Sep 2022.